Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, 2-Way Crossover Bioequivalence and Adhesion Study of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, 2-Way Crossover Bioequivalence and Adhesion Study of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Norelgestromin (Primary) ; Ethinylestradiol/norelgestromin
  • Indications Pregnancy
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 11 Jan 2020 Results assessing to establish the bioequivalence of a transdermal contraceptive patch containing the newly sourced adhesive component (test patch) and the currently marketed patch (reference patch) published in the Contraception
    • 15 Jun 2018 Status changed from recruiting to completed.
    • 03 Oct 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top